Table 3.
Regression rates of cervical lesions and HPV clearance rate at 2 months and 6 months for participants enrolled in a RCT of AV2 versus placebo in Kinshasa, DRC.
| 2 Months |
6 Months |
|||||
|---|---|---|---|---|---|---|
| AV2 | Placebo | AV2 | Placebo | |||
| VIA | n = 142 (%) | n = 131 (%) | P | n = 95 (%) | n = 94 (%) | P |
| Partial regression | 12 (8.5) | 14 (10.7) | 0.7 | 4 (4.2) | 4 (4.3) | 0.7 |
| Complete regression | 115 (80.9) | 106 (80.9) | 88 (92.6) | 85 (90.4) | ||
| Unchanged or progression | 15 (10.6) | 11 (8.4) | 3 (3.2) | 5 (5.3) | ||
| Cytology | n = 25 (%) | n = 27 (%) | n = 17 (%) | n = 24 (%) | ||
| Regression | 14 (56) | 13 (48.1) | 0.7 | 11 (64.7) | 11 (45.8) | 0.3 |
| Unchanged or progression | 11 (44) | 14 (51.9) | 6 (35.3) | 13 (54.2) | ||
| HPV infection | n = 41 (%) | n = 40 (%) | n = 27 (%) | n = 32 (%) | ||
| Complete clearance | 11 (26.8) | 14 (35) | 0.8 | 10 (37) | 11 (34.4) | 0.2 |
| Partial clearance | 3 (7.3) | 0 (0.0) | 4 (14.8) | 0 (0.0) | ||
| Persistence or new appearance | 27 (65.9) | 26 (65) | 13 (48.1) | 22 (68.8) | ||